4Romond E H, Perez E A, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer [J]. New Engl J Med, 2005,353 (16) : 1673-1684.
2Cady B.Breast cancer in the third millennium[J].J Surg Oncol,2001,77(4):225-232.
3Lara F,Delagarza J,Bamirez T,et al.High pathological complete response(PCR)afar neoadjuvant chemotherapy with doxoruhicin and docetaxel in locally advanced breast cancer[J].Proc Am Soc Clin Oncol,2000(19):126a.
4Henderson I C,Berry D,Demetri G D,et al.Improved outcomes from adding sequential paclitaxel but not from eslating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer[J].J Clin Oncol,2003,21(6):976-983.
5Shimizu T.Weekly administration of paclitaxel and pirarubicine for recurrent breast cancer[J].Gan To Kagaku Ryoho,2003,30(1):105-109.
6Garces C A,Cance W G.Neoadjuvant chemotherapy of breast cancer[J].Am Surg,2004,70(7):565-569.
7Hutcheon A W,Ogston K N,Heys S D,et al.Primary chemotherapy in the treatment of breast cancer:significantly enhanced clinical and pathological response with docetaxel[J].Proc Am Soc Clin Oncol,2000(19):83.
8Cance WG,Carey L A,Calvo B F,et al.Long-termoutcome of neoacljuvant therapy for locally advanced brast carcinoma:effective clinical downstaging allows breast preservation and predicts out-standing local control and survival[J].Ann Surg,2002,236(3):295-303.
9Slarnon DJ, Godolphin W, JonesL A, et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cabcer [J]. Science,1989,244 (4905):707-712.
9American College of Radiology (ACR). Breast imaging reporting and data system (BI2RADS)[M].Reston:Am College Radiol,1998.1290.
10Patel D K. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer[J].Pharmacotherapy:The Journal of Human Pharmacology & Drug Therapy,2008,(11):31S-41S.
